Inovio Pharmaceuticals (INO) Analysts See $0.22 EPS, Pingtan Marine Enterprise LTD Has 2.5 Sentiment

July 25, 2017 - By Marie Mckinney

Pingtan Marine Enterprise Ltd, formerly China Growth Equity Investment Ltd., is a blank check company. The company has market cap of $50.75 million. The Firm focuses to serve as a vehicle for the acquisition of an operating business in the People’s Republic of China. It currently has negative earnings. The Firm focuses to identify a prospective target business not be limited to a particular industry.

Analysts expect Inovio Pharmaceuticals Inc (NASDAQ:INO) to report $0.22 EPS on August, 11.They anticipate $0.00 EPS change or 0.00% from last quarter’s $0.22 EPS. T_INO’s profit would be $16.95M giving it 6.81 P/E if the $0.22 EPS is correct. After having $0.20 EPS previously, Inovio Pharmaceuticals Inc’s analysts see 10.00% EPS growth. About 1.01 million shares traded. Inovio Pharmaceuticals Inc (NASDAQ:INO) has declined 29.01% since July 25, 2016 and is downtrending. It has underperformed by 45.71% the S&P500.

Among 6 analysts covering Inovio Pharmaceuticals (NASDAQ:INO), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Inovio Pharmaceuticals had 19 analyst reports since August 10, 2015 according to SRatingsIntel. The company was maintained on Wednesday, September 9 by Maxim Group. The stock of Inovio Pharmaceuticals Inc (NASDAQ:INO) earned “Buy” rating by Maxim Group on Tuesday, January 5. PiperJaffray downgraded it to “Neutral” rating and $9 target in Thursday, March 16 report. H.C. Wainwright maintained Inovio Pharmaceuticals Inc (NASDAQ:INO) rating on Friday, July 7. H.C. Wainwright has “Buy” rating and $1300 target. On Thursday, June 1 the stock rating was maintained by Maxim Group with “Buy”. As per Monday, August 10, the company rating was maintained by Piper Jaffray. The firm has “Hold” rating given on Wednesday, August 12 by Zacks. The firm earned “Hold” rating on Friday, August 14 by Zacks. The firm has “Hold” rating given on Tuesday, August 9 by Maxim Group. Aegis Capital maintained the stock with “Buy” rating in Thursday, June 8 report.

Inovio Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The company has market cap of $461.54 million. The Company’s DNA immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It currently has negative earnings. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus.

Since January 1, 0001, it had 1 buying transaction, and 0 insider sales for $393,148 activity.

It is down 0.00% since July 25, 2016 and is . It has underperformed by 16.70% the S&P500.